Tumor necrosis factor and its targets in the inflammatory cytokine pathway are identified as putative transcriptomic biomarkers for escitalopram response.
Powell TR, Schalkwyk LC, Heffernan AL, Breen G, Lawrence T, Price T, Farmer AE, Aitchison KJ, Craig IW, Danese A, Lewis C, McGuffin P, Uher R, Tansey KE, D'Souza UM.
Powell TR, et al. Among authors: d souza um.
Eur Neuropsychopharmacol. 2013 Sep;23(9):1105-14. doi: 10.1016/j.euroneuro.2012.09.009. Epub 2012 Nov 9.
Eur Neuropsychopharmacol. 2013.
PMID: 23142150
Clinical Trial.